Clinical Hemostasis and Cerebrovascular Research Group

Group leader: Zsuzsa Bagoly MD, PhD

Members: Dóra Bomberák MSc; Rebeka Hodossy-Takács MD; Éva Katona PhD; Linda Lóczi MSc; Rita Orbán-Kálmándi MSc, PhD; Vivien Stercel MD; István Szegedi MD, PhD; Edina Székely PharmD

Technician: Gizella Haramura BSc

 

Background: Thrombotic disorders resulting in cardiovascular or cerebrovascular disease are among the leading causes of death in all developed countries. In acute ischaemic stroke thrombolysis is a safe and effective therapy in the majority of cases, however, the therapy may be ineffective in some patients, moreover, potentially fatal brain haemorrhage can develop as complication. As of today, the inefficacy of treatment or therapy-associated intracerebral hemorrhage cannot be foreseen at the initiation of thrombolysis and their exact pathomechanism remains unexplained. Similarly, the pathomechanism of bleeding or thrombotic complications in a number of haematological and immunological diseases is still not entirely clear as of today.

 

Areas of interest: Our research focuses on clinical and experimental research in the field of thrombosis and hemostasis. One of the main area of our research is the relationship between cerebrovascular diseases (stroke) and hemostasis. Our research group investigates potentially relevant hemostasis factors associated with the failure of acute ischaemic stroke treatments (intravenous thrombolysis and mechanical thrombectomy). By using blood samples of acute ischemic stroke patients stored in our biobank, we can observe the level and genetic variations of certain individual proteins involved in blood coagulation and compare the results with the outcome of the patients. Such observations may help to explain adverse outcomes and can serve as the basis for more effective treatments in the future. Our studies also include the investigation of haemostasis factors influencing the outcome of acute haemorrhagic stroke and the evolution of intracerebral haematoma.

In addition to the studies on cerebrovascular pathologies, another focus of our research group is to unravel the pathomechanisms of haemorrhagic or thrombotic complications in certain haematological, immunological (e.g. multiple myeloma, SLE, inflammatory bowel disease) and obstetric disorders. Our investigations also focus on the fibrinolytic system and rare disorders affecting the intricate balance of the fibrinolytic system. Part of our research work includes experimental studies on new types of antithrombotic agents. Our results may influence the development of new therapies targeting haemostasis, contribute to the identification of new thrombotic markers and to the development of novel laboratory diagnostic methods in the field of thrombosis and hemostasis.

 

Research techniques applied: all aspects of clinical research, handling of blood samples, biobanking, comprehensive assessment of wide range of haemostasis parameters from individual factor levels to global assays, specific fibrinolysis assays, testing for haemotasis polymorphisms, inflammatory markers, neutrophil extracellular traps, basic protein assays (e.g. SDS PAGE, Western blot), complex statistical methods.

 

List of the most relevant publications:

  1. Ghansah H, Orbán-Kálmándi R, Debreceni IB, Katona É, Rejtő L, Váróczy L, Lóczi L, de Laat B, Huskens D, Kappelmayer J, Bagoly Z. Low factor XIII levels and altered fibrinolysis in patients with multiple myeloma. Thromb Res. 2024;234:12-20. doi: 10.1016/j.thromres.2023.12.004.
  2. Stercel V, Lóczi L, Kadenczki O, Nemes É, Nagy B Jr, Hodossy-Takács R, Szabó AÁ, Fagyas M, Kappelmayer J, Szabó T, Bagoly Z. Effect of anti-SARS-CoV-2 BNT162b2 mRNA vaccination on thrombin generation in children with inflammatory bowel disease. Front Immunol. 2023;14:1257072. doi: 10.3389/fimmu.2023.1257072.
  3. Lóczi L, Orbán-Kálmándi R, Árokszállási T, Fekete I, Fekete K, Héja M, Tóth J, Csiba L, Bagoly Z. Thrombin generation as a predictor of outcomes in patients with non-traumatic intracerebral hemorrhage. Front Neurol. 2022;13:912664. doi: 10.3389/fneur.2022.912664.
  4. Székely EG, Orbán-Kálmándi R, Szegedi I, Katona É, Baráth B, Czuriga-Kovács KR, Lóczi L, Vasas N, Fekete I, Fekete K, Berényi E, Oláh L, Csiba L, Bagoly Z. Low α2-Plasmin Inhibitor Antigen Levels on Admission Are Associated With More Severe Stroke and Unfavorable Outcomes in Acute Ischemic Stroke Patients Treated With Intravenous Thrombolysis. Front Cardiovasc Med. 2022;9:901286. doi: 10.3389/fcvm.2022.901286.
  5.  Lóczi L, Orbán-Kálmándi R, Árokszállási T, Fekete I, Fekete K, Héja M, Tóth J, Csiba L, Bagoly Z. Thrombin generation as a predictor of outcomes in patients with non-traumatic intracerebral hemorrgage. Front Neurol. 2022;13:912664. doi: 10.3389/fneur.2022.912664.
  6. Orbán-Kálmándi R, Szegedi I, Sarkady F, Fekete I, Fekete K, Vasas N, Berényi E, Csiba L, Bagoly Z. A modified in vitro clot lysis assay predicts outcomes and safety in acute ischemic stroke patients undergoing intravenous thrombolysis. Sci Rep. 2021;11(1):12713. doi: 10.1038/s41598-021-92041-1.
  7. Szegedi I, Orbán-Kálmándi R, Nagy A, Sarkady F, Vasas N, Sik M, Lánczi LI, Berényi E, Oláh L, Crișan A, Csiba L. Bagoly Z. Decreased clot burden is associated with factor XIII Val34Leu polymorphism and better functional outcomes in acute ischemic stroke patients treated with intravenous thrombolysis. PLoS One. 2021;16(7):e0254253. doi: 10.1371/journal.pone.0254253.
  8. Orbán-Kálmándi R, Árokszállási T, Fekete I, Fekete K, Héja M, Tóth J, Sarkady F, Csiba L, Bagoly Z. A Modified in vitro Clot Lysis Assay Predicts Outcomes in Non-traumatic Intracerebral Hemorrhage Stroke Patients-The IRONHEART Study. Front Neurol. 2021;12:613441. doi: 10.3389/fneur.2021.613441. 
  9. Bagoly Z, Baráth B, Orbán-Kálmándi R, Szegedi I, Bogáti R, Sarkady F, Csiba L, Katona É. Incorporatin of α2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients. Biomolecules. 2021;11(3):347. doi: 10.3390/biom11030347.
  10. Szegedi I, Orbán-Kálmándi R, Csiba L, Bagoly Z. Stroke as a Potential Complication of COVID-19-Associated Coagulopathy: A Narrative and Systematic Review of the Literature. J Clin Med. 2020;9(10):3137. doi: 10.3390/jcm9103137.
  11. Szegedi I, Nagy A, Székely EG, Czuriga-Kovács KR, Sarkady F, Lánczi LI, Berényi E, Csiba L, Bagoly Z. PAI-1 5G/5G genotype is an independent risk of intracranial hemorrhage in post-lysis stroke patients. Ann Clin Transl Neurol. 2019;6(11):2240-2250. doi: 10.1002/acn3.50923.
  12. Bagoly Z, Szegedi I, Kálmándi R, Tóth NK, Csiba L. Markers of Coagulation and Fibrinolysis Predicting the Outcome of Acute Ischemic Stroke Thrombolysis Treatment: A Review of the Literature. Front Neurol. 2019;10:513. doi: 10.3389/fneur.2019.00513.
  13. Székely EG, Czuriga-Kovács KR, Bereczky Z, Katona É, Mezei ZA, Nagy A, Tóth NK, Berényi E, Muszbek L, Csiba L, Bagoly Z. Low factor XIII levels after intravenous thrombolysis predict short-term mortality in ischemic stroke patients. Sci Rep. 2018;8(1):7662. doi: 10.1038/s41598-018-26025-z.

Frissítés dátuma: 2024.04.11.